{"id":19,"date":"2026-03-04T10:19:56","date_gmt":"2026-03-04T10:19:56","guid":{"rendered":"https:\/\/medi-first-research.de\/?page_id=19"},"modified":"2026-03-18T10:39:57","modified_gmt":"2026-03-18T10:39:57","slug":"scientific-leadership","status":"publish","type":"page","link":"https:\/\/medi-first-research.de\/en\/scientific-leadership\/","title":{"rendered":"Scientific Leadership"},"content":{"rendered":"
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

Clinical responsibility and international research expertise.<\/h1>\n<\/div>\n\n\n\n

The scientific architecture of Medi First R&D follows a clear principle: technological innovation only becomes relevant when it is clinically actionable. Scientific leadership ensures that Target Product Profiles (TPP), formulation development, and evidence pathways do not stand side by side, but converge within a consistent methodology - with a clear safety logic and transparent decision criteria.<\/p>\n<\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
<\/div><\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
<\/div><\/div>\n\t\t
\n\t\t\t

Gabriel Hentschel (PhD Cand.)
\nHead of Scientific Strategy & Clinical Safety<\/p>\n<\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

Gabriel Hentschel (PhD Cand.)<\/h2>\n<\/div>\n\n\n\n\n
\n\t

Gabriel Hentschel directs the scientific strategy at the interface of research and clinical application. His profile combines scientific work in international contexts with clinical practice, with a focus including neurology\/epilepsy and clinical safety. At the center is transfer: from clinical requirements through the Target Product Profile (TPP) to protocols that structure evidence pathways and enable implementation.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

The profile: clinical safety as a methodological anchor<\/h2>\n<\/div>\n\n\n\n
<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
\n
\n
\n
\n \"\"\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t

01<\/p>\n<\/div>\n\n\n\n\n

\n\t

International perspective & scientific standards<\/h3>\n<\/div>\n\n\n\n\n
\n\t

Scientific work in international research and clinical environments sharpens the focus on comparability, methodology, and standards. This perspective informs program prioritization, endpoint definition, and the assessment of development options.<\/p>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
\n
\n
\n
\n \"\"\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t

02<\/p>\n<\/div>\n\n\n\n\n

\n\t

Focus: neurology & epilepsy<\/h3>\n<\/div>\n\n\n\n\n
\n\t

A key focus is on neurological questions and epileptological contexts, including pediatric perspectives. Central are safety parameters, tolerability, and dosability - as integral parts of the Target Product Profile (TPP) and formulation logic.<\/p>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
\n
\n
\n
\n \"\"\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t

03<\/p>\n<\/div>\n\n\n\n\n

\n\t

Clinical safety & acute medicine<\/h3>\n<\/div>\n\n\n\n\n
\n\t

Clinical safety is not understood as an after-the-fact check, but as a guiding principle throughout development. A background in clinical acute and emergency medicine (ATLS\/ALS) strengthens the focus on risk-benefit assessment, clear protocolization, and pragmatic implementation in everyday clinical practice - especially where decisions must be made under uncertainty.<\/p>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

In cannabinoid-based phytomedicine, credibility arises from methodological rigor.<\/h2>\n<\/div>\n\n\n\n\n
\n\t

Our goal is to develop profiles that can be standardized, dosed, and clinically evaluated - with special attention to tolerability, usability, and an evidence logic that supports clinical decisions.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \"\"\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div><\/div>
<\/div>
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t

Contact the scientific leadership<\/h2>\n<\/div>\n\n\n\n\n
\n\t

For institutional exchange, collaboration inquiries, or methodological questions, the scientific leadership is available to you directly.<\/p>\n<\/div>\n\n\n\n

<\/div><\/div>Request scientific dialogue<\/span><\/a>\n
\n\t

Note: Information and documents are provided on a project basis and subject to review (possibly NDA-based).<\/p>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Klinische Verantwortung und internationale Forschungsexpertise. Die wissenschaftliche Architektur von Medi First R&D folgt einem klaren Grundsatz: Technologische Innovation gewinnt erst dann an Relevanz, wenn sie klinisch anschlussf\u00e4hig wird. Scientific Leadership...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-19","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages\/19","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/comments?post=19"}],"version-history":[{"count":42,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages\/19\/revisions"}],"predecessor-version":[{"id":1152,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages\/19\/revisions\/1152"}],"wp:attachment":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/media?parent=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}